...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix Announces Corporate Update Conference Call ... Bear

Actually it's only page 200 of the entire doc and it concludes the following :

3P-MACE + Hosp CHF, baseline eGFR <60 ml/min with a P-Value = 0.02.

"Conclusion: Patients with T2D, ACS, and Stage 3 CKD have a very high risk of subse-quent MACE plus CHF hospitalization. The BET protein inhibitor ABP may reduce this risk."

That's all I see.

Koo

 

Share
New Message
Please login to post a reply